Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Extension

Other · developed by Corbus Pharmaceuticals

Phase 2 Most advanced trial (none active)

CRBP Developer

1 Registered trials

What is Extension?

Extension is the name given to an open-label extension study part in which JBT-101 is dosed at 20 mg twice daily for 364 days. The study is conducted in diffuse cutaneous systemic sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Dermatology
Developer: Corbus Pharmaceuticals Inc. (CRBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02465437	Phase 2	Diffuse Cutaneous Systemic Sclerosis	Terminated	CRBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Cutaneous Systemic Sclerosis

More from Corbus Pharmaceuticals

CRB-601 Phase 1/2 CRB-913 Phase 1 JBT-101 Phase 3 Sutantatug Envedotin Phase 3

Sources

ClinicalTrials.gov NCT02465437

Updated Oct 11, 2026. Something wrong or missing? Report it on the CRBP page.

Follow CRBP, the company behind Extension

See CRBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z